Core Viewpoint - A class action has been filed against Nektar Therapeutics for allegedly overstating the prospects of its REZOLVE-AA trial, which is critical for its lead product candidate, rezpegaldesleukin [1][2]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025 [1]. - Allegations include failure to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocol standards, which likely impacted the trial's results negatively [2]. - The complaint states that the integrity and prospects of the REZOLVE-AA trial were overstated, making public statements by the defendants materially false and misleading [2]. Group 2: Trial Results and Stock Impact - On December 16, 2025, Nektar announced that the REZOLVE-AA trial failed to reach statistical significance, attributing this to the inclusion of ineligible patients [3]. - Following this announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [3]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [3]. - Shareholders can choose to remain absent class members if they do not wish to participate in the case [3].

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics for alleged misleading statements regarding the REZOLVE-AA trial, impacting investors who acquired Nektar securities between February 26, 2025, and December 15, 2025 [2][7]. Allegation Details - The lawsuit claims that Nektar made false and misleading statements about the enrollment process in the REZOLVE-AA trial, which did not adhere to proper protocols, potentially affecting the trial's results [7]. - It is alleged that the integrity and prospects of the REZOLVE-AA trial were overstated, leading to material misrepresentation in public statements [7]. - Following the announcement of the trial's failure to reach statistical significance on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.77%, closing at $49.16 per share [7]. Next Steps - Investors who suffered losses and wish to discuss their legal rights or learn more about the claims are encouraged to contact the law firm Bragar Eagel & Squire [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Nektar to contact them to discuss legal options [1]. - A federal securities class action has been filed against Nektar, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Allegations Against Nektar - The complaint alleges that Nektar and its executives made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [5]. - Nektar's press release on December 16, 2025, revealed that the Phase 2b REZOLVE-AA trial failed to reach statistical significance due to the inclusion of ineligible patients [6]. - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [7].

Core Viewpoint - Nektar Therapeutics is facing a securities fraud lawsuit due to allegations of concealing enrollment protocol failures in its clinical trials, which has led to significant investor losses [1][2]. Group 1: Financial Impact - Nektar shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, following the revelation that four ineligible patients were enrolled in the pivotal REZOLVE-AA study [2]. - The company completed a $115 million underwritten public offering on July 2, 2025, selling 4,893,618 shares at $23.50 per share [6]. Group 2: Timeline of Events - On February 26, 2025, Nektar announced the completion of target enrollment in the Phase 2b REZOLVE-AA trial, emphasizing strict eligibility criteria [6]. - During a Q4/FY 2024 earnings call on March 12, 2025, management highlighted operational features aimed at minimizing clinical operational risk and reiterated the trial's eligibility criteria [6]. - On December 16, 2025, Nektar disclosed that the trial narrowly missed its primary endpoint and that four patients had major eligibility violations [6]. Group 3: Allegations of Misconduct - The lawsuit alleges that Nektar's management consistently cited enrollment criteria as evidence of trial rigor while being aware of violations of those criteria [3]. - Specific allegations include that two patients had unstable alopecia areata diagnosed less than six months before randomization, and two others began treatment before completing the required eight-week washout period [3]. Group 4: Legal Proceedings - Investors who suffered losses between February 26, 2025, and December 15, 2025, may be entitled to recover damages, with the deadline to apply for lead plaintiff status closing on May 5, 2026 [1][4].

Core Viewpoint - Robbins LLP is urging stockholders of Nektar Therapeutics to participate in a class action lawsuit due to alleged misstatements regarding the company's clinical trial results [1][2]. Group 1: Class Action Details - A class action was filed on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025 [1]. - The allegations include that Nektar overstated the prospects of its REZOLVE-AA trial, failing to disclose issues with trial enrollment and its potential negative impact on results [2]. Group 2: Trial Results and Stock Impact - On December 16, 2025, Nektar announced that the Phase 2b REZOLVE-AA trial did not achieve statistical significance, leading to a stock price drop of $4.14 per share, or 7.77%, closing at $49.16 [3]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [3]. Group 4: Firm Background - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Nektar to contact them for discussing legal options [1]. - The firm has set a deadline of May 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Nektar [2]. - The complaint alleges that Nektar and its executives made false statements regarding the REZOLVE-AA trial, which could significantly impact the trial's results and integrity [5]. Group 2: Trial Results and Stock Impact - On December 16, 2025, Nektar announced that the Phase 2b REZOLVE-AA trial failed to reach statistical significance, attributing this to the inclusion of ineligible patients [6]. - Following the announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [7].

Core Viewpoint - Nektar Therapeutics is facing a securities fraud class action lawsuit due to misleading statements and failure to disclose material facts regarding the Phase 2b REZOLVE-AA trial results for its alopecia areata treatment, rezpegaldesleukin, which did not meet statistical significance [2][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Nektar securities between February 26, 2025, and December 15, 2025, with a deadline to file a lead plaintiff motion by May 5, 2026 [1][4]. - The lawsuit alleges that Nektar made materially false and misleading statements and failed to disclose adverse facts about the company's business and trial results [3]. - Specific allegations include improper enrollment in the REZOLVE-AA trial, which was likely to negatively impact the trial's results and overstated the trial's integrity and prospects [3]. Group 2: Impact on Stock Price - Following the announcement of the trial results on December 16, 2025, Nektar's stock price fell by $4.14, or 7.8%, closing at $49.16 per share, resulting in financial harm to investors [2][3].

Abivax - Abivax is developing obefazimod, a potential blockbuster therapy for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis and phase 2b trials for Crohn's disease [2][3] - The ulcerative colitis market is projected to grow from $8.7 billion in 2026 to $14.3 billion by 2035, indicating significant market potential for obefazimod [4] - Abivax has seen a share price increase of over 1,900% in the past year, driven by positive clinical trial results and rumors of potential buyout interest from companies like Eli Lilly and AstraZeneca [6] - The company reported €589.7 million (approximately $697 million) in cash and equivalents, sufficient to fund operations into Q4 2027 [8] Nektar Therapeutics - Nektar's lead candidate, rezpegaldesleukin, has shown promising results in phase 2b trials for moderate-to-severe atopic dermatitis, with over 80% of patients achieving significant skin improvement [10] - The drug is also being tested for multiple indications, including alopecia areata, type 1 diabetes, and multiple sclerosis, enhancing its potential as a "pipeline-in-a-drug" [11] - Following a $460 million capital raise, Nektar has over $700 million in liquidity, allowing it to fund operations into 2027, with analysts projecting significant upside in stock price [12] - Nektar is considered a potential acquisition target for larger pharmaceutical companies, including Sanofi and AbbVie, which could see strategic value in its pipeline [13]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics due to allegations of violations of federal securities laws related to misleading statements and trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Nektar between February 26, 2025, and December 15, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Nektar, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Nektar - The complaint alleges that Nektar and its executives made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [4]. - Nektar's press release on December 16, 2025, revealed that the Phase 2b REZOLVE-AA trial failed to reach statistical significance due to the inclusion of ineligible patients [5]. Group 3: Market Impact - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share on December 16, 2025 [6].

Core Viewpoint - Nektar Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding patient enrollment compliance in its pivotal REZOLVE-AA clinical trial, which has raised concerns about the integrity of the trial results [1][4][6]. Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025, and December 15, 2025 [2]. - Nektar's shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, following the disclosure of enrollment violations in the REZOLVE-AA trial [3]. - Investors have until May 5, 2026, to seek lead plaintiff status in the lawsuit [3]. Group 2: Clinical Trial Enrollment Issues - The REZOLVE-AA trial required strict patient eligibility criteria, including a SALT score between 50 and 100, stable disease for at least six months, and completion of an eight-week washout period from prior medications [3]. - The lawsuit claims that Nektar failed to enforce these standards, resulting in the randomization of four ineligible patients, which constituted over 4% of the total 94 patients randomized [4][5]. - The trial's primary endpoint narrowly missed statistical significance when including the ineligible patients, with p-values of 0.186 and 0.121 for the two dosing arms [5]. Group 3: Management's Misrepresentation - Nektar management allegedly misled investors by claiming adherence to trial protocols while ineligible patients were enrolled [6]. - The complaint highlights a significant gap between Nektar's representations about its enrollment procedures and the actual practices at its trial sites [4]. - Joseph E. Levi, Esq. emphasized that shareholders deserve accurate information regarding the integrity of the clinical enrollment process [7].